Cochrane · systematic review · CD008244
Milnacipran for pain in fibromyalgia in adults
Cording, M, Derry, S, Phillips, T, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
Pain, Palliative and Supportive CareAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
4
No studies
1
Included studies
NR
No studies 1 · 14.3%Ungraded 2 · 28.6%Very low 0 · 0%Low 1 · 14.3%Moderate 1 · 14.3%High 2 · 28.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison
Population: adults with fibromyalgia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Milnacipran 100 mg/day | no estimate extracted | 100 participants | Ungraded |
At least 50% reduction in pain or equivalent (substantial) | no estimate extracted | 2 studies · 1250 participants | Moderate |
At least 30% reduction in pain or equivalent (moderate) | no estimate extracted | 3 studies · 1925 participants | High |
Adverse event withdrawals | no estimate extracted | 4 studies · 2379 participants | High |
Serious adverse events | no estimate extracted | 4 studies · 2378 participants | Low |
Death | no estimate extracted | NR | No studies |
Milnacipran 200 mg/day | no estimate extracted | 200 participants | Ungraded |